Henry Ford Hospital
- Type
- Teaching hospital
- Where
- Detroit, MI
- Medicare CCN
- 230053
- Received
- $22,578,842 in 2,255 records, 2025 ($2,374,187 general, $20,204,655 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: HENRY FORD HOSPITAL Fuzzy (name and state)
- Patent assignee: Henry Ford Hospital Fuzzy (name and state)
- Trademark owner: HENRY FORD HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 306 | $2,374,187 |
| 2025 | Research payment | 1,949 | $20,204,655 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,949 | $20,204,655 |
| Grant | 53 | $1,085,570 |
| Space rental or facility fees (teaching hospital only) | 143 | $525,389 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 56 | $297,590 |
| Consulting Fee | 9 | $194,038 |
| Royalty or License | 2 | $114,055 |
| Education | 16 | $77,445 |
| Long term medical supply or device loan | 7 | $44,579 |
| Debt forgiveness | 14 | $20,362 |
| Gift | 3 | $13,000 |
| Charitable Contribution | 1 | $2,000 |
| Travel and Lodging | 1 | $96 |
| Food and Beverage | 1 | $60 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | PFIZER INC. | $70,380 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $67,900 | Research payment | In-kind items and services | Biological, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatm | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $56,170 | Research payment | In-kind items and services | XTANDI Drug, ONCOLOGY | A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participant | 2025 |
| 2025-12-31 | Vasc-Alert LLC | $54,055 | Royalty or License (4 payments) | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Merck Sharp & Dohme LLC | $37,491 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $35,559 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $31,894 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $20,020 | Research payment | In-kind items and services | LAGEVRIO Biological, INFECTIOUS DISEASE | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupirav | 2025 |
| 2025-12-31 | PFIZER INC. | $19,215 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $17,540 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2025 |
| 2025-12-31 | Siemens Medical Solutions USA, Inc. | $13,200 | Research payment | Cash or cash equivalent | Varian Ethos Treatment Planning Device, Oncology | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $11,215 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $10,300 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $8,000 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $7,028 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $7,019 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $5,183 | Research payment | In-kind items and services | DOCETAXEL Drug, ONCOLOGY | A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resista | 2025 |
| 2025-12-31 | Stryker Corporation | $5,056 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Merck Sharp & Dohme LLC | $4,253 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2025 |
| 2025-12-31 | Stryker Corporation | $3,808 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | PFIZER INC. | $3,567 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-12-31 | ABBVIE INC. | $3,537 | Research payment | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upad | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $3,481 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab MK-3475 Versus Placebo in Participants wit | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $3,327 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Intuitive Surgical, Inc. | $3,000 | Long term medical supply or device loan | In-kind items and services | ION Device, SURGERY | 2025 | |
| 2025-12-31 | Sequel Med Tech, LLC | $2,400 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $2,273 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $1,834 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy | 2025 |
| 2025-12-31 | Stryker Corporation | $1,530 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | ABBVIE INC. | $1,529 | Research payment | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult | 2025 |
| 2025-12-31 | Viseon, Inc. | $1,245 | Debt forgiveness | In-kind items and services | MaxView System - Lateral Set Device, Spinal Surgery | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $1,116 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Trial of Pembrolizumab MK-3475 in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Partici | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | ABBVIE INC. | $600 | Research payment | In-kind items and services | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combin | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $533 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monothera | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | ADVITA ORTHO, LLC | $425 | Research payment | Cash or cash equivalent | EQUINOXE Device, ORTHOPAEDIC | CR09-005 EQUINOXE PMCF | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $336 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel,Nab-Paclitaxel Chemotherapy with or without Pembro | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $274 | Research payment | In-kind items and services | LAGEVRIO Biological, INFECTIOUS DISEASE | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupirav | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $175 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | DJO, LLC | $100 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Tanabe Pharma America, Inc. | $70 | Research payment | In-kind items and services | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon | 2025 | |
| 2025-12-30 | Novocure Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Optune Lua (NovoTTF-200T) Device, Oncology | 2025 | |
| 2025-12-29 | E.R. Squibb & Sons, L.L.C. | $4,982 | Research payment | Cash or cash equivalent | Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commer | 2025 | |
| 2025-12-25 | PFIZER INC. | $6,388 | Research payment | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | ELRANATAMAB POST TRIAL ACCESS AN OPENLABEL SINGLEARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER | 2025 |
| 2025-12-25 | Janssen Research & Development, LLC | $4,996 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 | |
| 2025-12-25 | ABBVIE INC. | $187 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $1,580 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $1,300 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2025 |
| 2025-12-23 | Daiichi Sankyo Inc. | $4,550 | Research payment | Cash or cash equivalent | DS7300-189 | 2025 | |
| 2025-12-23 | Daiichi Sankyo Inc. | $3,000 | Research payment | Cash or cash equivalent | DS7300-189 | 2025 | |
| 2025-12-23 | Daiichi Sankyo Inc. | $2,500 | Research payment | Cash or cash equivalent | DS7300-189 | 2025 | |
| 2025-12-23 | Daiichi Sankyo Inc. | $500 | Research payment | Cash or cash equivalent | DS7300-189 | 2025 | |
| 2025-12-22 | Aveo Pharmaceuticals, Inc. | $3,747 | Research payment | Cash or cash equivalent | FOTIVDA Drug, Oncology | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2025 |
| 2025-12-22 | Ionis Pharmaceuticals, Inc. | $2,839 | Research payment | Cash or cash equivalent | IS744CS7 | 2025 | |
| 2025-12-22 | SANOFI US SERVICES INC. | $2,000 | Research payment | Cash or cash equivalent | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension St | 2025 | |
| 2025-12-22 | Genmab A/S | $455 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diff | 2025 |
| 2025-12-19 | Medtronic, Inc. | $45,188 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2025 |
| 2025-12-19 | TransMedics, Inc. | $38,125 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OCS Lung TOP Regisry | 2025 |
| 2025-12-19 | Takeda Pharmaceuticals U.S.A., Inc. | $20,152 | Research payment | Cash or cash equivalent | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-2 | 2025 | |
| 2025-12-19 | Abbott Laboratories | $7,495 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | NCT06707688--Abbott Medical - VERITAS Study | 2025 |
| 2025-12-19 | PFIZER INC. | $6,000 | Research payment | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTE | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | $3,254 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINA | 2025 |
| 2025-12-19 | Incyte Corporation | $2,707 | Research payment | Cash or cash equivalent | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | 2025 | |
| 2025-12-19 | Medtronic, Inc. | $2,635 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2025 |
| 2025-12-19 | Genentech, Inc. | $2,308 | Research payment | Cash or cash equivalent | Evaluation of Fenebrutinib in RMS patients | 2025 | |
| 2025-12-18 | BIOTRONIK INC. | $13,000 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | Janssen Research & Development, LLC | $5,228 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $552 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $357 | Research payment | Cash or cash equivalent | PK Papyrus Device, Cardiology/Vascular Diseases | PK Papyrus-Registry | 2025 |
| 2025-12-17 | PFIZER INC. | $36,995 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-12-17 | Bolton Medical Inc | $4,561 | Research payment | Cash or cash equivalent | TREO ABDOMINAL STENT-GRAFT SYSTEM Device, ENDOVASCULAR AORTIC REPAIR | TREO PAS | 2025 |
| 2025-12-17 | PFIZER INC. | $3,963 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-12-17 | Janssen Research & Development, LLC | $2,400 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination wi | 2025 | |
| 2025-12-17 | Novartis Pharmaceuticals Corporation | $1,800 | Research payment | Cash or cash equivalent | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Partici | 2025 | |
| 2025-12-17 | Bolton Medical Inc | $1,150 | Research payment | Cash or cash equivalent | TREO ABDOMINAL STENT-GRAFT SYSTEM Device, ENDOVASCULAR AORTIC REPAIR | TREO PAS | 2025 |
| 2025-12-17 | Novartis Pharmaceuticals Corporation | $775 | Research payment | Cash or cash equivalent | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2025 | |
| 2025-12-16 | Incyte Corporation | $13,000 | Research payment | Cash or cash equivalent | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 | |
| 2025-12-16 | Medtronic, Inc. | $7,004 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2025 |
| 2025-12-16 | Boston Scientific Corporation | $2,225 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | SIMPLAAFY | 2025 |
| 2025-12-16 | Gilead Sciences, Inc. | $2,153 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o | 2025 |
| 2025-12-15 | Janssen Research & Development, LLC | $35,500 | Research payment | Cash or cash equivalent | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants W | 2025 | |
| 2025-12-15 | Janssen Research & Development, LLC | $15,372 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Po | 2025 |
| 2025-12-15 | Zimmer Biomet Holdings, Inc. | $9 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-12 | TransMedics, Inc. | $186,600 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OLP-2 Liver Registry | 2025 |
| 2025-12-12 | SK Life Science, Inc. | $10,076 | Research payment | Cash or cash equivalent | XCOPRI Drug, Neurology | YKP3089C049 | 2025 |
| 2025-12-12 | Teva Pharmaceuticals USA, Inc. | $136 | Research payment | In-kind items and services | PROAIR RESPICLICK Drug, Respiratory | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of | 2025 |
| 2025-12-11 | Merck Sharp & Dohme LLC | $16,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers | 2025 |
| 2025-12-11 | Edwards Lifesciences Corporation | $11,798 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2025 | |
| 2025-12-11 | ABBVIE INC. | $6,902 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2025 |
| 2025-12-11 | Tanabe Pharma America, Inc. | $6,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerabilit | 2025 | |
| 2025-12-11 | ABBVIE INC. | $5,991 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $4,488 | Research payment | Cash or cash equivalent | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANT | 2025 | |
| 2025-12-11 | Incyte Corporation | $2,856 | Research payment | Cash or cash equivalent | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | 2025 | |
| 2025-12-11 | Tanabe Pharma America, Inc. | $2,272 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerabilit | 2025 | |
| 2025-12-11 | Celgene Corporation | $788 | Research payment | Cash or cash equivalent | Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells. A prospective study for the long-term | 2025 | |
| 2025-12-11 | Teva Pharmaceuticals USA, Inc. | $533 | Research payment | Cash or cash equivalent | Albuterol sulfate Drug, Pulmonary/Respiratory Diseases | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of | 2025 |
| 2025-12-10 | Merck Sharp & Dohme LLC | $70,091 | Research payment | Cash or cash equivalent | LAGEVRIO Biological, INFECTIOUS DISEASE | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupirav | 2025 |
| 2025-12-10 | TransMedics, Inc. | $35,800 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OLP Liver Registry | 2025 |
| 2025-12-10 | Mannkind Corporation | $22,953 | Research payment | Cash or cash equivalent | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | 2025 | |
| 2025-12-10 | Mannkind Corporation | $10,750 | Research payment | Cash or cash equivalent | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | 2025 | |
| 2025-12-10 | Mannkind Corporation | $7,950 | Research payment | Cash or cash equivalent | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | 2025 | |
| 2025-12-10 | Brainlab, Inc. | $3,580 | Grant | In-kind items and services | Curve and software / instruments Device, Surgical planning and navigation radiation treatment planning and positioning | 2025 | |
| 2025-12-10 | Mannkind Corporation | $2,500 | Research payment | Cash or cash equivalent | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | 2025 | |
| 2025-12-10 | Penumbra, Inc. | $558 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2025 |
| 2025-12-09 | PFIZER INC. | $1,696 | Research payment | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | ELRANATAMAB POST TRIAL ACCESS AN OPENLABEL SINGLEARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER | 2025 |
The latest 200 records of 2,255.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Detroit, MI | County Wayne County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 638,530 | 1,772,259 | 10,077,761 |
| Population, 2020 census P1 | 639,111 | 1,793,561 | 10,077,331 |
| Median age B01002 | 35.2 | 37.9 | 40.2 |
| Under 18 B01001 | 24.8% | 23.6% | 21.2% |
| 65 and over B01001 | 15.1% | 16.6% | 18.6% |
| Households B11001 | 257,998 | 700,591 | 4,076,369 |
| Foreign born B05002 | 6.6% | 10.3% | 7.2% |
| Median household income B19013 | $39,938 | $60,539 | $72,875 |
| Median family income B19113 | $49,398 | $79,522 | $93,357 |
| Per capita income B19301 | $24,594 | $34,906 | $40,735 |
| Poverty rate B17001 | 32.7% | 20.8% | 13.2% |
| Unemployment rate B23025 | 14.0% | 8.7% | 5.7% |
| Civilian labor force B23025 | 268,955 | 828,838 | 5,018,449 |
| Mean commute (minutes) B08013 | 24.8 | 24.7 | 24.2 |
| Bachelor's degree or higher B15003 | 18.1% | 27.6% | 32.4% |
| Housing units B25001 | 329,393 | 801,083 | 4,622,236 |
| Owner-occupied B25003 | 50.3% | 64.8% | 73.2% |
| Renters B25003 | 49.7% | 35.2% | 26.8% |
| Median home value B25077 | $83,900 | $178,500 | $231,600 |
| Median gross rent B25064 | $1,074 | $1,132 | $1,129 |
| White, not Hispanic B03002 | 10.8% | 47.9% | 72.4% |
| Black B03002 | 75.0% | 36.6% | 13.1% |
| Hispanic or Latino B03002 | 8.3% | 6.9% | 5.9% |
| Asian B03002 | 1.7% | 3.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.
Comments